Latest Breaking News On - Sutro xpress - Page 8 : comparemela.com

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSutro biopharmaMaggie bellerAnniej changSutro xpressCelgene corporationExchange commissionMerck kgaSutro biopharma incMerck kgaaBristol myers squibbBill newellChief executive officerSouth san franciscoOrphan drug designationMyers squibb

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Santa clara universityUnited statesSouth san franciscoSan carlosComunidad autonoma de catalunaMaggie bellerSutro xpressSutro biopharmaAnniej changArturo molinaDavid paulingGenentech rocheOaknin benzaquenLuniversidad complutenseShabbir anikUniversity of california

Sutro Biopharma Announces Closing of Upsized $144 9 Million Public Offering, including Full Exercise

Search jobs 11-Dec-2020 Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., Dec. 11, 2020 /PRNewswire/ Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the closing of its upsized public offering of 6,900,000 shares of its common stock at a public offering price of $21.00 per share, which includes the exercise in full of the underwriters option to purchase 900,000 shares of common stock. The gross proceeds from this offering were $144.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.

United statesNew yorkWedbush pacgrowSutro biopharmaAnniej changDavid schullPiper sandlerSutro xpressBroadridge financial solutionsEquity syndicate departmentCelgene corporationExchange commissionWells fargo securitiesProspectus departmentSutro biopharma incPiper sandler co

Sutro Biopharma Announces Closing of Upsized $144 9 Million Public Offering, including Full Exercise of the Underwriters Option to Purchase Additional Shares

Share this article Share this article SOUTH SAN FRANCISCO, Calif., Dec. 11, 2020 /PRNewswire/ Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the closing of its upsized public offering of 6,900,000 shares of its common stock at a public offering price of $21.00 per share, which includes the exercise in full of the underwriters option to purchase 900,000 shares of common stock. The gross proceeds from this offering were $144.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.

United statesNew yorkWedbush pacgrowSutro biopharmaAnniej changDavid schullPiper sandlerSutro xpressBroadridge financial solutionsEquity syndicate departmentCelgene corporationExchange commissionWells fargo securitiesProspectus departmentSutro biopharma incPiper sandler co